Study Comparing Lymphoseek® vs. Albumin Nanocolloid in Head and Neck, Melanoma and Breast Cancer

Inclusion Criteria: * Written informed consent * Histologically confirmed diagnosis of melanoma, breast cancer or head and neck cancer and candidate for surgical resection with lymph node mapping being a part of the surgical plan. * At least 18 years of age at the time of consent. * The subject is clinically node negative (cN0) at the time of screening. * In Melanoma Patients * Diagnosis of primary melanoma with sentinel node indication ( \>0.8 mm Breslow thickness; clinically negative lymph nodes) * In Breast Cancer Patients * T1-T2 N0 breast cancer. * Patients with pure ductal carcinoma in situ (DCIS) if lymph node biopsy is part of the surgical plan. * In Oral cavity tumors patients * T1-T2 N0 oral cavity squamous cell carcinoma Exclusion Criteria: * Pregnancy or lactation * Clinical or radiological evidence of metastatic cancer including palpably abnormal or enlarged lymph nodes * Patients that have had preoperative chemotherapy, immunotherapy or radiation therapy * Patients who have undergone node basin surgery of any type or radiation to the nodal basin(s) potentially draining the primary tumor * Patients who have undergone a wide excision for their tumor or complex reconstruction (rotation, free flap or skin graft of any type).